Baseline data from the phase 2 eDREAM trial presented this week at the EURETINA 2026 Congress in Vienna support patient-tailored microperimetry as a potential functional measure for geographic atrophy (GA) clinical trials, according to Galimedix Therapeutics.

The approach uses retinal imaging to create a lesion-specific testing grid for each patient, with microperimetry measuring sensitivity at locations surrounding the atrophic area. The resulting functional map can then be compared with retinal structure on optical coherence tomography (OCT).

Baseline testing showed good short-term repeatability. Investigators also compared best-corrected visual acuity, low-luminance visual acuity, and central microperimetric sensitivity and found no systematic bias between repeat tests. Averaging 2 baseline tests reduced measurement error.

When microperimetry was correlated with OCT, photoreceptor disruption that colocalized with retinal pigment epithelium damage strongly predicted focal scotomas. Investigators also identified locations where structural appearance and measured retinal function did not correspond.

eDREAM is a randomized, double-masked, placebo-controlled study evaluating GAL-101 eye drops in 110 patients with GA. Its primary endpoint is change in GA lesion growth measured by fundus autofluorescence. The findings reported at EURETINA are baseline measurements and do not assess GAL-101 treatment efficacy. RP